NewcelX Ltd.
For the period ended Jun 30, 2026. Filed Sep 18, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Jun 30, 2026 · Filed Sep 18, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.2 · Operating Activities
Operating Activities
Net cash used in operating activities for the six months ended June 30, 2026, was $2,872 thousand, representing an increase of $2,270 thousand compared to $602 thousand for the six months ended June 30, 2025.
The increase in cash used in operating activities was primarily driven by higher operating cash burn following the first-time consolidation of NLS operations, public company compliance costs, and continued clinical development of our lead NCEL-101 program for T1D, as well as working capital changes.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.